Filing Flows › Companies › Avalo Therapeutics › Timeline
Avalo Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−55.1% to $6.93
Avalo Therapeutics (AVTX) stock fell 55% over the last 252 sessions, to $6.93. On the way it reported 5 quarters, its insiders filed 2 open-market trades and 5 Form 144 notices of planned sales, and the company filed 6 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 38.0% | −6.4% (−1.9% vs SPY) | — | — |
| Aug 18, 2026 | Form 144 | Form 144: Christopher Ryan Sullivan plans to sell $622K | −1.2% (−0.5% vs SPY) | −3.5% (−2.3% vs SPY) | −18.5% (−16.1% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Christopher Ryan Sullivan plans to sell $75K | +1.8% (+2.3% vs SPY) | +1.2% (+2.6% vs SPY) | −19.8% (−17.3% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Christopher Ryan Sullivan plans to sell $1.4M | +1.8% (+2.3% vs SPY) | +1.2% (+2.6% vs SPY) | −19.8% (−17.3% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Mittie Doyle plans to sell $99K | +1.8% (+2.3% vs SPY) | +1.2% (+2.6% vs SPY) | −19.8% (−17.3% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Jennifer Riley plans to sell $52K | −1.5% (−1.2% vs SPY) | +0.9% (+1.0% vs SPY) | −8.2% (−6.8% vs SPY) |
| Aug 11, 2026 | Insider sale | Riley Jennifer sold $52K | −1.5% (−1.2% vs SPY) | +0.9% (+1.0% vs SPY) | −8.2% (−6.8% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: missed the EPS estimate by -34.5% | −0.8% (−0.6% vs SPY) | +3.7% (+3.4% vs SPY) | +0.9% (+0.4% vs SPY) |
| Jun 23, 2026 | 8-K | Directors and officers: departures, appointments, pay | +4.3% (+5.8% vs SPY) | +12.2% (+12.6% vs SPY) | +6.1% (+5.7% vs SPY) |
| Jun 12, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.1% (−2.8% vs SPY) | +14.6% (+14.0% vs SPY) | +22.8% (+20.9% vs SPY) |
| Jun 8, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.3% (+1.5% vs SPY) | +13.6% (+11.5% vs SPY) | +44.8% (+42.9% vs SPY) |
| May 13, 2026 | Earnings | Earnings: beat the EPS estimate by 8.6% | −0.5% (−1.0% vs SPY) | −20.3% (−19.7% vs SPY) | −37.7% (−37.7% vs SPY) |
| May 7, 2026 | 8-K | Material definitive agreement | −5.9% (−6.7% vs SPY) | −18.5% (−20.7% vs SPY) | −58.5% (−59.5% vs SPY) |
| Apr 28, 2026 | 8-K | Material definitive agreement | −11.4% (−11.0% vs SPY) | −4.5% (−4.9% vs SPY) | +9.1% (+4.3% vs SPY) |
| Mar 27, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.3% (+0.6% vs SPY) | +15.8% (+12.0% vs SPY) | −7.7% (−19.3% vs SPY) |
| Mar 23, 2026 | Earnings | Earnings: beat the EPS estimate by 75.3% | +0.6% (−0.5% vs SPY) | +3.4% (+5.7% vs SPY) | +6.3% (−2.0% vs SPY) |
| Nov 14, 2025 | Insider sale | Goldman Jonathan sold $163K | +2.6% (+2.6% vs SPY) | +18.6% (+21.6% vs SPY) | +18.4% (+17.1% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: missed the EPS estimate by -33.7% | −6.5% (−5.4% vs SPY) | −6.4% (−7.3% vs SPY) | +6.5% (+5.3% vs SPY) |
Insiders’ record here
In the year on the chart, Avalo Therapeutics' insiders reported 0 open-market buys ($0) and 2 sales ($215K). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −2.9%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Avalo Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.